Shared crawled corpus for the Clinical evidence source target. Use this Space as a grounding library, not as a generic writing persona.

Source target: web_clinical_evidence
Ranking guidance: Prioritize clinical guidelines, systematic reviews, RCTs, trial registrations, regulator labels, and high-quality cohort studies. Surface population, intervention, comparator, outcomes, trial phase/status, dates, and limitations.

Answer behavior: lead with the clearest source-backed finding, preserve source provenance, surface dates and trust signals, state uncertainty when evidence is incomplete, and avoid unsupported synthesis.

Clinical evidence from guidelines, trials, biomedical literature, regulator material, and evidence reviews.

Clinical Evidence Library

This is a retrospective look at registry quality signals in ClinicalTrials.gov, not a report of current performance.
The registry-record analysis examined 79,413 ClinicalTrials.gov records.
In the planned-analysis sample, 61% of first primary outcome entries were too vague to identify a measurement or domain.
The posted-results review analyzed 2,178 publicly posted results records.
Among posted results records, 20% reported more than two primary outcomes, and sponsors or investigators self-repor

The 2023 PCOS guideline builds on the 2018 guidance rather than overturning it. Its core remains the same, but the diagnostic pathway is clearer: in adults, AMH can be used as an alternative to ultrasound.

That change is limited to adults. The evidence base has improved, but remains generally low to moderate quality, so the guidelines still call for much more research.

Q1. According to the systematic review, which task did AI methods appear to be used for most often in evidence synthesis workflows?
- Study screening
- Data extraction
- Risk-of-bias assessment
- Selective reporting detection
Answer: Study screening
Q2. What did the review say about the reported benefits of AI for data extraction?
- They were clearly established and fully reliable
- They were ambiguous, so reliability is not supported
- They were absent because data extraction was never attempte

Long-acting growth hormone in children: current consensus and where it fits
The current consensus is that long-acting growth hormone (LAGH) is a meaningful once-weekly alternative to daily recombinant human growth hormone for children with growth hormone deficiency, with phase 3 trials showing non-inferior efficacy and similar short-term safety, while guidelines and best-practice use are still evolving.
The main clinical message from the attached sources is not that weekly therapy is universally

ClinicalTrials.gov as evidence for semaglutide vs tirzepatide weight loss
ClinicalTrials.gov is best treated as a **complement** to journal publications, not a replacement. For semaglutide and tirzepatide weight-loss comparisons, it can add protocol-level details and posted summary results, but it does not by itself provide a complete or fully validated comparative evidence base.
The registry is useful because each trial record has a unique NCT identifier, structured registration fields, a Histo